Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment Review H1 2015

1. Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 30-Jun-2015 No. of pages: 431 Single User License: US $2000 Browse more Reports on cancer therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

2. Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015 This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

3. Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : 4SC AG, AbbVie Inc., Actinium Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Amgen Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BoehringerIngelheim GmbH, Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Celgene Corporation, Conkwest, Inc., Cornerstone Pharmaceuticals, Inc., CTI BioPharma Corp. and some more.. Drugs Profile Discussed in this Research : 4SC-202, AG-120, alvocidib hydrochloride, AMG-232, AT-9283, BI-836858, binimetinib, bortezomib, brentuximabvedotin, burixafor, cabozantinib s-malate, cafusertib hydrochloride, CB-839, CC-90007, Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia, Cell Therapy to Target CD33 for Acute Myeloid Leukemia, Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies, CPI-613 and more… ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

4. Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015 Scope For Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015 • The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Refractory Acute Myeloid Leukemia and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Refractory Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

5. Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

6. Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441